India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced its filing of a provisional patent for the treatment of multiple types of eating disorders by a method and combination of cannabis extracts and other compounds. Should this filing result in the issuance of a patent, IGC intends to develop its IGC-506 candidate for both human and veterinary use. “The development of cannabis-based combination therapies represents a large, unique opportunity, and we believe we are the first mover in this emerging specialty-pharmaceutical sector,” Ram Mukunda, chief executive officer of IGC, stated in this morning’s news release. “Over the past three years, we have built a strong IP portfolio and now propose to obtain funding to commence pre-clinical and clinical trials as appropriate. Securing FDA approval for combination therapies is generally much faster and less expensive than the process for new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner.” The company’s patent portfolio currently includes IGC-501 for the treatment of neuropathic pain, IGC-502 for the treatment of seizures and IGC-504 for eating disorders, including cachexia.
Read the full article
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Read More